New urine test may spare bladder cancer patients from overtreatment

NCT ID NCT07252297

Ongoing Diagnosis Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a test that checks for a specific gene marker (SIX6) in urine or tissue can predict if bladder cancer will come back after surgery. Researchers will compare SIX6 levels in 177 patients who had low-risk bladder cancer to see if the test can tell who is likely to have a recurrence. If it works, doctors could use this test to avoid giving extra treatments to patients who don't need them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIX6 Gene Methylation Assay
What this could lead to: If successful, this test could help doctors better predict which bladder cancer patients are at risk of recurrence, allowing for more personalized treatment and fewer unnecessary therapies.
What could go wrong: This is a small, retrospective study, so results may not apply to all patients. The test is still experimental and needs larger trials to confirm its accuracy and usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

Xi Jing Hopspital

Xi'an, ShannxI, 710300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.